Marshall Wace
PCRX icon

Marshall Wace’s Pacira BioSciences PCRX Stock Holding History

Marshall Wace’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Buy
+129,348
New +$3.06M ﹤0.01% 1588
2025
Q3 		– Sell
-190,366
Closed -$4.55M – 3278
2025
Q2 		$4.55M Buy
+190,366
New +$4.8M 0.01% 1187
2025
Q1 		– Sell
-42,613
Closed -$803K – 2976
2024
Q4 		$803K Sell
42,613
-482,336
-92% -$8.47M ﹤0.01% 1832
2024
Q3 		$7.9M Sell
524,949
-446,194
-46% -$7.63M 0.01% 845
2024
Q2 		$27.8M Buy
971,143
+159,791
+20% +$4.55M 0.04% 401
2024
Q1 		$23.7M Buy
811,352
+331,159
+69% +$10.2M 0.04% 458
2023
Q4 		$16.2M Sell
480,193
-5,452
-1% -$160K 0.03% 539
2023
Q3 		$14.9M Buy
485,645
+97,348
+25% +$3.51M 0.03% 516
2023
Q2 		$15.6M Buy
388,297
+69,136
+22% +$2.86M 0.03% 572
2023
Q1 		$13M Buy
319,161
+193,804
+155% +$7.71M 0.03% 615
2022
Q4 		$4.84M Buy
125,357
+82,396
+192% +$4.01M 0.01% 1207
2022
Q3 		$2.29M Buy
42,961
+24,638
+134% +$1.37M 0.01% 1918
2022
Q2 		$1.07M Buy
+18,323
New +$1.2M ﹤0.01% 2405
2022
Q1 		– Sell
-205,322
Closed -$12.4M – 3854
2021
Q4 		$12.4M Buy
205,322
+190,381
+1,274% +$10.5M 0.02% 721
2021
Q3 		$837K Buy
+14,941
New +$861K ﹤0.01% 2124
2021
Q2 		– Sell
-30,624
Closed -$2.15M – 2974
2021
Q1 		$2.15M Buy
+30,624
New +$2.19M 0.01% 1292
2020
Q1 		– Sell
-19,673
Closed -$891K – 1956
2019
Q4 		$891K Sell
19,673
-253,489
-93% -$10.8M 0.01% 1014
2019
Q3 		$10.4M Buy
+273,162
New +$10.9M 0.08% 282
2016
Q4 		– Sell
-10,749
Closed -$368K – 1090
2016
Q3 		$368K Buy
+10,749
New +$421K ﹤0.01% 835
2015
Q4 		– Sell
-54,226
Closed -$2.23M – 1087
2015
Q3 		$2.23M Buy
+54,226
New +$3.32M 0.03% 426

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's PCRX Position: Q2 2026 in Review

Marshall Wace opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 129,348 shares worth $3.28M. The stake represents ﹤0.01% of the portfolio and ranks #1588 among its holdings. This is a return to the name: Marshall Wace previously reported a position in PCRX as recently as Q2 2025.

Marshall Wace first reported a position in PCRX in Q3 2015 and has held it in 20 quarters since. The position peaked at $27.8M in Q2 2024. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Marshall Wace held 129,348 shares of Pacira BioSciences worth $3.28M as of Q2 2026.
  • Pacira BioSciences was a new Marshall Wace position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1588 holding.
  • Marshall Wace first reported a position in Pacira BioSciences in Q3 2015 and has held it in 20 quarters since.
  • Marshall Wace's Pacira BioSciences position peaked at $27.8M in Q2 2024.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.